Dose-Response Relationship, Immunologic
"Dose-Response Relationship, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
| Descriptor ID |
D004306
|
| MeSH Number(s) |
G12.300
|
| Concept/Terms |
Dose-Response Relationship, Immunologic- Dose-Response Relationship, Immunologic
- Dose Response Relationship, Immunologic
- Immunologic Dose-Response Relationship
- Dose-Response Relationships, Immunologic
- Immunologic Dose Response Relationship
- Immunologic Dose-Response Relationships
- Relationships, Immunologic Dose-Response
- Relationship, Immunologic Dose-Response
- Relationship, Immunologic Dose Response
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Immunologic".
This graph shows the total number of publications written about "Dose-Response Relationship, Immunologic" by people in this website by year, and whether "Dose-Response Relationship, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dose-Response Relationship, Immunologic" by people in Profiles.
-
Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020 07; 20(7):851-863.
-
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016 08; 16(8):923-34.
-
A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015 Jun 09; 33(25):2944-54.
-
Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
-
Interleukin-8 fails to induce human immunodeficiency virus-1 expression in chronically infected promonocytic U1 cells but differentially modulates induction by proinflammatory cytokines. Immunology. 2000 Sep; 101(1):140-6.
-
Impaired interleukin-8-induced degranulation of polymorphonuclear neutrophils from human immunodeficiency virus type 1-infected individuals. Clin Diagn Lab Immunol. 1999 May; 6(3):345-51.